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Abstract
Introduction: The aim of this study was to examine whether circulating levels of the proinflammatory glycoprotein
tenascin-C (TNC) are useful as an activity-specific or predictive biomarker in systemic lupus erythematosus (SLE).
Methods: Serum TNC levels were determined by enzyme-linked immunosorbent assay at inception visit in a
prospective cohort of 59 SLE patients, and in 65 healthy controls (HC). SLE patients were followed for a mean of
11 months, disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000
(SLEDAI-2 K) and British Isles Lupus Assessment Group disease activity index (BILAG-2004), clinical and laboratory
data were recorded every 3–6 months, and changes in glucocorticoids (GC) and immunosuppressants (IS) were
recorded serially. We examined cross-sectionally the relationships between serum concentrations of TNC and SLE
status, SLEDAI-2 K scores, strata of disease activity, and levels of conventional biomarkers [anti–double-stranded
DNA (dsDNA), anti-nucleosome antibodies, C3 and C4]. We also explored the utility of TNC levels for predicting
disease flares, defined as (i) new/increased GC, (ii) new/increased GC or IS, and (iii) increase in SLEDAI by ≥3 or
(iv) BILAG A or B flare.
Results: There was no significant difference in the mean levels of TNC between the SLE patients and HC. However, in
SLE patients with active disease (SLEDAI ≥6), the TNC levels were significantly higher than in the HC (p = 0.004) or in
patients with no/low disease activity (p = 0.004). In SLE patients, TNC levels were significantly associated with positivity
of anti-dsDNA (p = 0.03) and anti-nucleosome antibodies (p = 0.008). Flares defined by a need to escalate
immunosuppressive therapy were captured more frequently and earlier than flares defined by standard activity indices.
Higher baseline levels of serum TNC presented a significantly greater risk of flare (i) [hazard ratio (HR) 1.39, 95 %
confidence interval (CI) 1.11–1.73] or (ii) (HR 1.25, 95 % CI 1.02–1.52) but not of flares (iii) or (iv). The baseline serum TNC
level was the single most important independent predictor of flare (i) compared with conventional biomarkers.
Conclusions: TNC is not disease-specific, but it seems to indicate the activity of SLE and may predict the need to escalate
immunosuppressive therapy. TNC levels may thus serve as a useful activity-specific and predictive biomarker in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by a wide range of mani-
festations involving nearly all organs, including the skin,
kidney, lung, brain, heart and joints. Its precise aetio-
pathogenesis remains unclear. Diverse serological and
clinical manifestations as well as unpredictable flares
and remissions are observed among patients with SLE,
and they present a challenge for the evaluation of disease
activity and administration of appropriate treatment. Al-
though clinical assessment is the cornerstone of manage-
ment of patients with SLE, these evaluations are limited
and require additional instruments to confirm the diag-
nosis and determine disease activity.
Traditional serological biomarkers such as anti-dsDNA
antibodies and complement levels have been proven to be
neither reliable indicators of disease activity [1, 2] nor
predictors of impending disease flares [3]. The lack of
useful biomarkers for SLE hampers assessment of disease
activity and impedes the evaluation of treatment re-
sponse. For this reason, there is growing interest in the
exploration of new biomarkers for use as surrogate
markers of disease activity and/or to predict flares of the
disease.
Tenascin-C (TNC) is a large extracellular matrix
glycoprotein that belongs to the damage-associated mo-
lecular patterns family [4]. Little TNC is found in most
healthy adult tissues, because it is specifically induced
and tightly controlled during acute inflammation and
persistently expressed during chronic inflammation [5–11].
The induction of TNC is highly associated with a wide
range of diseases related to inflammation, including pneu-
monitis [12], hepatitis [13], inflammatory bowel disease
[14], myocarditis [15], atherosclerosis [16], obesity [17],
rheumatoid arthritis [18] and the enthesitis-related arthritis
category of juvenile idiopathic arthritis [19]. An early in-
flammatory response is generally associated with enhanced
TNC levels, both in the plasma and in tissue [6]. Thus,
plasma levels of TNC have been shown to be useful indica-
tors for chronic hepatitis C [13], inflammatory bowel dis-
ease [14] and myocarditis [15].
To date, no researchers have reported whether circu-
lating TNC levels could reflect disease activity and/or
early tissue damage in SLE. Using clinical and laboratory
data from our prospective cohort of patients with SLE,
we investigated the association of serum TNC levels
with Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2 K) scores and conventional la-
boratory markers of disease activity, such as anti–
double-stranded DNA antibodies (anti-dsDNA), C3, C4
and anti-nucleosome antibodies. Moreover, we tested
the clinical utility of serum TNC levels for the identifica-
tion of patients with active disease and the prediction of
disease flares.
Material and methods
Subjects and data collection
Fifty-nine patients fulfilling the revised 1997 American
College of Rheumatology classification criteria for SLE
[20] were recruited from the Institute of Rheumatology,
Prague, and prospectively followed according to a prede-
fined protocol. Clinical and laboratory assessments were
performed at baseline, after 3 months, after 6 months
and every 6 months thereafter. At each per-protocol
visit, disease activity was assessed using the SLEDAI-2 K
[21] and the British Isles Lupus Assessment Group dis-
ease activity index (BILAG-2004) [22], and the current
dosage of glucocorticoids (GC) and each immunosup-
pressant (IS) medication prescribed for SLE were re-
corded, in addition to previous changes in medication
updated from the source documentation. Patients were
followed longitudinally for a mean of 10.8 months
[standard deviation (SD) 6.5]. Healthy controls (HC; n = 65)
were also recruited. All study participants were ≥18 years of
age, and each participant provided written informed con-
sent. The study design and written consent were approved
by our institution’s ethics committee.
Definitions
Because we were interested mainly in global SLE activity,
our primary outcome definitions were based on the
SLEDAI-2 K. The scores for the clinical items of the
SLEDAI-2 K (c-SLEDAI-2 K) were calculated by sub-
tracting the contribution of hypocomplementaemia and
anti-dsDNA positivity from the total SLEDAI-2 K score.
Active disease was defined as a SLEDAI-2 K score ≥6
[23]. A disease flare was defined as (i) new/increased
GC, (ii) new/increased GC or IS, (iii) an increase in the
SLEDAI-2 K ≥3 and (iv) BILAG-2004 A or B flare. For
analytical purposes, SLEDAI-2 K items describing the
involvement of one organ or tissue were consolidated
into a single SLEDAI-2 K domain (neuropsychiatric
features = seizure, psychosis, organic brain syndrome,
cranial nerve disorder, lupus headache, cerebrovascular
accident; renal features = haematuria, proteinuria, pyuria,
urinary casts; serositis = pleurisy, pericarditis; haemato-
logical features = thrombocytopenia, leukopenia).
Laboratory analysis
Fasting blood samples were collected from all patients dur-
ing the baseline visit. The samples were immediately centri-
fuged and stored at −80 °C. Levels of TNC in the serum
samples were determined using the human TNC Large (FN
III-B) Assay enzyme-linked immunosorbent assay (ELISA)
kit from IBL (Fujioka, Japan). The samples were diluted
400-fold. The absorbance was measured using an ELISA
reader (SUNRISE; Tecan, Grödig, Austria) using 450 nm as
the primary wavelength. The intra- and inter-assay coeffi-
cients of variation for this ELISA were 6.4 % and 3.5 %,
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respectively, at concentrations of 5.43 ng/ml and 6.55 ng/ml.
The sensitivity for this kit was 44 pg/ml.
The routine laboratory and immunological measure-
ments needed for the calculation of the SLEDAI-2 K were
performed at every visit, and other routine immunological
tests [anti-nuclear antibodies (ANA), ANA line immuno-
assay (LIA) and anti-nucleosome antibodies) were mea-
sured at the baseline visit. ANA antibodies were detected
by indirect immunofluorescence (Immuno Concepts,
Sacramento, CA, USA) and further characterized by
the LIA method (IMTEC, Wiesbaden, Germany). Anti-
dsDNA antibodies were detected by immunofluorescence
(Immuno Concepts); normal was defined as a negative
titre. Anti-nucleosome antibodies were measured by
ELISA (EUROIMMUN, Lübeck, Germany); normal was
defined as 0–24 U/ml. Complement levels were measured
using the AU system with reagents (Beckman Coulter,
Brea, CA, USA). The reference range for C3 in the serum
was 0.9–1.8 g/L, and for C4 it was 0.1–0.4 g/L.
Statistical analysis
Continuous variables were expressed as the mean ± SD.
Categorical data were summarized as absolute frequencies
and percentages. We used univariate and multivariable
(with adjustments for age and sex) linear regression ana-
lyses to assess the association between the baseline serum
TNC levels and clinical and laboratory manifestations of
SLE. We derived survival curves using the Kaplan-Meier
method, and Cox proportional hazards models were used
to analyse the association between baseline serum TNC
levels and prospectively measured indicators of disease
flares. The results were presented as hazard ratio (HR) and
95 % confidence interval (CI). Serum TNC levels were ana-
lysed as a continuous variable, with HRs calculated per
100 ng/ml increment of serum TNC. The relationship be-
tween serum TNC levels and the risk of endpoint was ex-
amined in unadjusted and multivariable adjusted Cox
models. The Akaike information criterion (AIC) was used
to compare the ability of each immunological marker to
predict disease flares, and the differences between predict-
ive models were tested using the likelihood ratio test. Re-
ceiver operating characteristic (ROC) curve analysis was
performed using data from the inception visit to establish
the optimal discriminatory threshold to identify patients
with active disease (defined as SLEDAI-2 K ≥ 6) and to pre-
dict (i) flares based on TNC levels. A two-tailed p value
<0.05 was considered statistically significant. Statistical ana-
lyses were performed using IBM SPSS version 22 software
(IBM SPSS, Armonk, NY, USA).
Results
Demographic and clinical characteristics of patients with SLE
The SLE cohort consisted of 93 % women with a mean
(±SD) age of 44 ± 16 years. At baseline, 95 % were
ANA-positive, 39 % were anti-dsDNA–positive, 46 %
were anti-nucleosome antibody–positive and 49 %
had low serum complement (C3, C4 or both). The
mean (±SD) SLEDAI-2 K was 3.7 ± 3.5, the disease
duration was 7 ± 7 years, 33 % had active disease as
defined by a SLEDAI-2 K ≥6, 59 % were using oral
GC, 42 % were using anti-malarials and 20 % were
using IS. The HC were somewhat older, and males
were more often represented. The baseline character-
istics of the SLE cohort and the demographics of the
HC are summarized in Table 1.
Table 1 Baseline characteristics
SLE (n = 59) Healthy controls
(n = 65)
Female sex 55 (93 %) 45 (69 %)
Age, yr 44 ± 16 48 (14)
Caucasian 59 (100 %) 65 (100 %)
Disease duration, yr 7 ± 7
SLICC/ACR Damage Index 0.8 ± 1.4
SLEDAI-2 K 3.7 ± 3.5
cSLEDAI-2 K (only clinical SLEDAI-2 K items) 2.2 ± 3.0
SLEDAI-2 K ≥4 30 (53 %)
SLEDAI-2 K ≥6 19 (33 %)
Any SLEDAI-2 K clinical features 26 (45 %)
Neuropsychiatric featuresa 2 (3 %)
Vasculitisa 0 (0 %)
Arthritisa 10 (17 %)
Myositisa 0 (0 %)
Renal featuresa 8 (14 %)
Rasha 9 (15 %)
Alopeciaa 5 (9 %)
Mucosal ulcersa 0 (0 %)
Serositisa 1 (2 %)
Haematological featuresa 3 (5 %)
Fevera 0 (0 %)
Increased DNA bindinga 22 (38 %)
Low complementa 28 (48 %)
Anti-nucleosome antibody–positive 25 (46 %)
Oral glucocorticoids 35 (59 %)
Immunosuppressants 15 (25 %)
ANA anti-nuclear antibodies, SLEDAI-2 K Systemic Lupus Erythematosus Disease
Activity Index 2000, anti-dsDNA anti–double-stranded DNA, SLICC/ACR Systemic
Lupus International Collaborating Clinics/American College of Rheumatology,
SLE systemic lupus erythematosus
Data are presented as number and percentage or mean and
standard deviation
aAccording to SLEDAI-2 K definitions; renal, haematological, serositis and
neuropsychiatric SLEDAI-2 K features were merged into one item (see Definitions
section in text)
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Serum TNC levels in patients with SLE and healthy
controls
There was no significant difference in the mean levels of
TNC between the patients with SLE and HC (533 ±
192 ng/ml vs. 487 ± 164 ng/ml, p = 0.151). However, in
patients with SLE with active disease (SLEDAI-2 K ≥6) the
TNC levels were significantly higher than in the HC
(634 ± 254 ng/ml vs. 487 ± 164 ng/ml, p = 0.004) or patients
with no or low disease activity (634 ± 254 ng/ml vs. 481 ±
135 ng/ml, p = 0.004) (Fig. 1). We found no association
between age, sex and TNC levels (see Additional file 1).
Association between circulating levels of TNC and
measures of disease activity
A cross-sectional correlation and univariate linear regres-
sion analysis between serum TNC levels and SLEDAI-2 K
(β = 14, 95 % CI −1 to 29, r = 0.25, p = 0.061) and c-
SLEDAI-2 K (β = 16, 95 % CI −0.7 to 33, r = 0.25, p = 0.060)
at baseline visit showed a trend towards a positive correl-
ation, although the results were not statistically significant.
Patients with SLE with active involvement of at least one
SLEDAI-2 K domain (see Definitions section) have sig-
nificantly higher TNC levels than patients with no clinical
involvement according to SLEDAI-2 K (β = 108, 95 % CI
8–207, p = 0.035), and patients with any active item in the
renal SLEDAI-2 K domain had significantly higher TNC
levels than patients without active renal SLEDAI-2 K
features (see Table 2 and Additional file 2). The cross-
sectional associations between TNC and BILAG-2004
organ domains are shown in Additional file 2. (Note that
the renal BILAG-2004 domain could not be properly
assessed at inception visit, while its evaluation is heavily
dependent on previous measurements which were not
captured in our database.)
Serum TNC levels discriminate between active and
inactive disease
ROC curve analysis was performed to establish the opti-
mal discriminatory threshold to identify patients with
active disease (defined as SLEDAI-2 K ≥6) based on
TNC levels (Fig. 2). At the optimal cutoff point of
659 ng/ml, the area under the curve for TNC serum
levels that discriminated between active and inactive dis-
ease was 0.69 (95 % CI 0.53–0.86, p = 0.02) with a sensi-
tivity of 53 % and specificity of 92 %.
Association between circulating levels of TNC and
conventional laboratory parameters
A cross-sectional univariate linear regression and/or cor-
relation analysis between serum TNC levels and other la-
boratory measurements in patients with SLE at the initial
visit was performed (Table 2 and Additional file 3a, b).
The TNC levels in patients with SLE were positively corre-
lated with positivity for anti-dsDNA antibodies (β = 115,
95 % CI 12–218, p = 0.029) and anti-nucleosome anti-
bodies (β = 138, 95 % CI 38–238, p = 0.008). Associations
between TNC and these parameters were statistically sig-
nificant even after adjustment for age and sex. In contrast,
we did not find a significant association between serum
TNC levels and C3/C4 levels.
Serum TNC levels are predictive of disease flares
Flares defined by a need to escalate immunosuppressive
therapy [(i), (ii)] were captured more frequently and earl-
ier than flares defined by standard activity indices [(iii),
(iv)] (Fig. 3). Higher levels of serum TNC presented a
significantly greater risk of flare (i) (defined as the need
to start or escalate GC) (HR 1.39, 95 % CI 1.11–1.73) or
(ii) (defined as the need to start or escalate any IS) (HR
1.25, 95 % CI 1.02–1.52), but not of flare (iii) (defined as
an increase in SLEDAI-2 K ≥3) (HR 1.19, 95 % CI 0.87–
1.63) or (iv) defined as a BILAG-2004 flare A or B
(Table 3).
We also conducted a separate analysis in which serum
TNC levels were treated as a categorical variable. We
used the value of 659 ng/ml from the previous ROC
curve analysis as a cutoff to identify patients with active
disease. This value was almost identical to the value of
654 ng/ml generated by a separate ROC curve analysis
to find an optimal discriminatory threshold to identify
patients predicted to experience flare (i). In accordance
with the result above, the risk of flare (i) or (ii) was sig-
nificantly higher in the group of patients with higher
TNC levels (Table 3, Fig. 4).
Fig. 1 Mean levels of tenascin-C in healthy controls and patients with
systemic lupus erythematosus with low [Systemic Lupus Erythematosus
Disease Activity Index 2000 (SLEDAI-2 K) <6] and high (SLEDAI-2 K ≥6)
disease activity
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Serum TNC levels outperformed traditional biomarkers in
the prediction of flare (i)
Next, we compared the performance of univariate models
based either on traditional biomarkers (i.e., anti-dsDNA
or anti-nucleosome antibodies and C3 or C4) or serum
TNC levels to predict flare (i) using the AIC. As shown in
Table 4, serum TNC levels outperformed traditional bio-
markers when treated as both a continuous variable and a
categorical variable.
Discussion
In this study, we found that high TNC levels reflected
disease activity and predicted the escalation of GC or
other immunosuppressive therapies. To the best of our
knowledge, this is the first study to examine in detail the
role of TNC in patients with SLE.
An important prerequisite for testing a biomarker in a
new clinical setting is its biological plausibility. SLE is a
complex autoimmune disease characterized by enhanced
autoantibody formation, excessive proinflammatory cyto-
kine production and damage to multiple organ systems.
TNC is a proinflammatory extracellular matrix glycopro-
tein that has been shown to be involved in the regulation
of both innate and adaptive immune systems and to con-
trol the expression of various cytokines and the recruit-
ment of immune cells to sites of inflammation or injury
Table 2 Cross-sectional associations between serum TNC levels and clinical and laboratory parameters of patients with SLE at the
inception visit (univariate and age- and sex-adjusted regression analyses)
Univariate analyses Age– and sex–adjusted analyses
Variable β valueb (95 % CI) p Value β valueb (95 % CI) p Value
Patients with SLE vs. HC 46 (−17 to 110) 0.151 44 (−24 to 112) 0.205
Patients with SLE with SLEDAI-2 K ≥6 vs. HC 147 (50–245) 0.004 139 (34– 245) 0.010
Patients with SLE with SLEDAI-2 K ≥6 vs. SLEDAI-2 K <6 153 (50–256) 0.004 161 (54–267) 0.004
Patients with SLE (categorical variables)
Any SLEDAI-2 K clinical features (yes vs. no) 107.8 (8.1–207.4) 0.035 108.4 (3.6–213.3) 0.043
Neuropsychiatric clinical featuresa (yes vs. no) −211.9 (−488.9 to 65.2) 0.131 −202.5 (−485.8 to 80.8) 0.158
Vasculitisa (yes vs. no) – – – –
Arthritisa (yes vs. no) 48.3 (−87.7 to 184.2) 0.480 46.0 (−94.4 to 186.4) 0.514
Myositisa (yes vs. no) – – – –
Renal featuresa (yes vs. no) 265.2 (133.5–396.9) <0.001 269.7 (135.9–403.5) <0.001
Rasha (yes vs. no) −2.1 (−144.6 to 140.4) 0.977 −9.1 (−154.9 to 136.6) 0.901
Alopeciaa (yes vs. no) −84.6 (−267.0 to 97.8) 0.357 −85.0 (−270.7 to 100.7) 0.363
Mucosal ulcersa (yes vs. no) – – – –
Serositisa (yes vs. no) 231.1 (−160.4 to 622.6) 0.242 216.6 (−187.5 to 620.7) 0.287
Haematological featuresa (yes vs. no) 20.4 (−212.5 to 253.3) 0.861 9.1 (−231.3 to 249.5) 0.940
Fevera (yes vs. no) – – – –
Anti-dsDNA antibodies IF (positive vs. negative) 115 (12–218) 0.029 112 (3–221) 0.044
Complement C3/C4 (low vs. normal) −4 (−107 to 99) 0.938 −14 (−123 to 94) 0.793
Anti-nucleosome antibodies (positive vs. negative) 138 (38–238) 0.008 131 (30–234) 0.013
Patients with SLE (continuous variables)
SLEDAI-2 K 14 (−1 to 29) 0.061 14 (−1.5 to 30) 0.074
cSLEDAI-2 K (only clinical SLEDAI-2 K items) 16 (−1 to 33) 0.060 16 (−1.0 to 34) 0.065
C3, g/L −9 (−209 to 192) 0.931 5 (−205 to 216) 0.958
C4, g/L −232 (−695 to 230) 0.319 −210 (−694 to 273) 0.386
Anti-nucleosome antibodies, U −0.2 (−0.7 to 0.3) 0.403 −0.2 (−0.7 to 0.3) 0.460
Anti-dsDNA antibodies, titre 27 (−22 to 75) 0.266 30 (−21 to 81) 0.230
Urinary protein/creatinine ratio, mg/mmol 270 (101–439) 0.002 271 (98–444) 0.003
CI confidence interval, HC healthy controls, IF immunofluorescence, anti-dsDNA anti–double-stranded DNA, SLEDAI-2 K Systemic Lupus Erythematosus Disease
Activity Index 2000
aAccording to SLEDAI-2 K definitions; renal, haematological, serositis and neuropsychiatric SLEDAI-2 K features were merged into one item (see Definitions section of text)
bThe regression coefficient β corresponds to the difference in TNC levels between groups (when assessing categorical variables) or to the change in TNC
associated with a 1 unit increase in the assessed variable (when assessing continuous variables)
Boldface type indicates statistically significant values
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[7–11]. Little or no TNC is found in most healthy adult
tissues, but it is upregulated under pathological conditions
accompanying tissue injury and inflammation in many dif-
ferent organs that may be involved in the SLE disease
process, including the joints [8, 18], skin [24], kidney [25],
lungs [26], heart [27] and central nervous system [28].
Therefore, TNC seems to be an eligible candidate sur-
rogate marker of ongoing tissue damage and may reflect
disease activity or an impending flare. Moreover, TNC
expression was previously shown to have some applica-
tions in disease diagnosis and outcome prognostication
in immune-mediated and other inflammatory diseases
[7–19, 24–28].
The initial cross-sectional correlation analyses ap-
peared to support the utility of TNC as a putative SLE
biomarker. At the inception visit in our SLE cohort,
TNC levels were significantly associated with positivity
of anti-dsDNA and anti-nucleosome antibodies. Add-
itionally, there was a trend towards a positive correlation
with the SLEDAI-2 K and c-SLEDAI-2 K scores. Inter-
estingly, patients with SLE with active renal involvement
(mainly with proteinuria) had significantly higher TNC
levels than other patients with SLE. This finding is in
line with other observations of increased local expres-
sion or increased TNC circulating levels in patients with
different types of renal disease [29–31].
During the process of validation of a biomarker for the
assessment of disease activity, the first external criterion
to be correlated with the biomarker may be dichotom-
ous (i.e., active vs. inactive SLE) [32]. To delineate active
disease from inactive disease, we chose the robust defin-
ition of SLEDAI-2 K ≥6 that has been used in most clin-
ical SLE trials [23]. We found that mean TNC levels in
patients with SLE with active disease were significantly
higher than those of patients with SLE with no or low
disease activity or those of HC. High serum TNC levels
showed 53 % sensitivity and 92 % specificity in a ROC
curve analysis. Hence, TNC levels could be a useful
marker for distinguishing active from inactive SLE.
We also investigated the ability of serum TNC levels
to predict disease flares. Higher baseline levels of serum
TNC showed a significantly greater risk of a disease
flare, defined as the need to start or escalate GC or other
immunosuppressive therapy but not a flare defined as a
change in the SLEDAI-2 K ≥3 or a BILAG-2004 A or B
flare. There is no clear consensus on the best definition
of a flare in SLE or on the minimal clinically important
change that would be both sensitive and specific [33].
We used four definitions to define disease flares: two
based on a change in immunosuppressive therapy [(i)
and (ii)] and two based on a change in SLEDAI-2 K or
BILAG-2004 [(iii) and (iv)]. The Kaplan-Meier curves in
Fig. 2 Receiver operating characteristic curve analysis of tenascin (TNC) serum levels as a predictor of active systemic lupus erythematosus
(defined as Systemic Lupus Erythematosus Disease Activity Index 2000≥ 6). At the optimal cutoff point of 659 ng/ml, the area under the curve
for TNC serum levels that discriminated between active and inactive disease was 0.69 (95 % CI 0.53–0.86, p = 0.02) with a sensitivity of 53 % and
specificity of 92 %
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Fig. 3 illustrate the dynamics of the sensitivity of differ-
ent flare definitions in our cohort study. SLEDAI-2 K
and BILAG-2004 scores were collected only at prespeci-
fied time points (months 0, 3 and 6 and then every
6 months) and reflected only the SLE activity within a
maximum 30-day time window before each visit. At each
per protocol visit, however, the study nurse, by using the
source documentation, could retrospectively track any
changes in immunosuppressive therapy that had hap-
pened since the previous visit, and thus these data have
finer granularity in time and reflect more comprehen-
sively the course of the disease. Owing to the size of our
Fig. 3 Differential in time to flare according to the definitions of flare used. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI)
and British Isles Lupus Assessment Group disease activity index (BILAG) scores were collected only at prespecified time points (months 0, 3 and 6
and then every 6 months; however, the graphed points are exact dates when the per-protocol visits actually occurred), and reflected only the systemic
lupus erythematosus activity within a maximum 30-day time window before each visit. Changes in glucocorticoids and/or immunosuppressive therapy
were tracked using the source documentation, and thus these data have finer granularity in time (analysis with the Kaplan-Meier approach for survival
estimation). GC glucocorticoids, IS immunosuppressants
Table 3 Performance of baseline tenascin-C levels to predict disease flares (Cox proportional hazards analysis)
Univariate analyses Age and sex adjusted analyses
Flare definition HR (95 % CI) p Value HR (95 % CI) p Value
Tenascin as continuous variable
(i) New/increased GC 1.39 (1.11–1.73) 0.004 1.37 (1.11–1.70) 0.004
(ii) New/increased GC or IS 1.25 (1.02–1.52) 0.028 1.23 (1.01–1.49) 0.035
(iii) Increase in SLEDAI-2 K ≥3 1.19 (0.87–1.63) 0.277 1.21 (0.86–1.68) 0.270
(iv) BILAG-2004 flare A or B 1.10 (0.91–1.34) 0.323 1.09 (0.89–1.32) 0.403
Tenascin as categorical variable (>659 ng/ml)a
(i) New/increased GC 3.77 (1.60–8.88) 0.002 3.57 (1.48–8.59) 0.005
(ii) New/increased GC or IS 2.45 (1.10–5.46) 0.028 2.23 (0.98–5.08) 0.056
(iii) Increase in SLEDAI-2 K ≥3 1.42 (0.28–7.21) 0.672 1.52 (0.27–8.64) 0.636
(iv) BILAG-2004 flare A or B 1.74 (0.75–4.04) 0.197 1.64 (0.70–3.88) 0.257
BILAG-2004 British Isles Lupus Assessment Group disease activity index, CI confidence interval, HR hazard ratio, IS immunosuppressants, GC glucocorticoids, SLEDAI-2 K
Systemic Lupus Erythematosus Disease Activity Index 2000
aThe threshold value of 659 ng/ml for tenascin-C (TNC) was generated using receiver operating characteristic curve analysis of the relationship between active
systemic lupus erythematosus (SLEDAI-2 K ≥6) and baseline TNC
Boldface type indicates statistically significant values
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study sample, we preferred to have a more sensitive tool.
Hence, our primary definition of the flares was based on
the recorded new start or dose escalation of GC. Be-
cause GC are still considered to be the most effective
treatment for SLE, the need to start or escalate GC
seems to be both a sensitive and a pragmatic outcome
measurement of a disease flare. However, the addition of
an immunosuppressant may not always mirror an
increase in SLE activity; it may also represent a steroid-
sparing strategy. Flare definitions based on change in the
SLEDAI-2 K also have several limitations. For example,
the SLEDAI-2 K does not capture mild degrees of activ-
ity in some organ systems, does not have descriptors for
several types of activity (e.g., haemolytic anaemia) and
cannot capture worsening of activity in an organ system
descriptor [33]. Consequently, even lower SLEDAI-2 K
Fig. 4 Differentials in time to (a) flare (i) and (b) flare (ii) according to the baseline level of serum tenascin-C. Flare (i) was defined as the need to
start or escalate glucocorticoids, and flare (ii) was defined as the need to start or escalate any immunosuppressant (analysis with the Kaplan-Meier
approach for survival estimation). CI confidence interval
Table 4 A comparison of the performance of conventional biomarkers vs. tenascin-C to predict the escalation of glucocorticoids in
patients with SLE
Cox model Variable
Continuous AIC C3 C4 Anti-dsDNA Anti-nucleosome Tenascin
AIC 165.02 163.52 162.67 161.87 160.40
C3 165.02 1.000 0.220 0.125 0.076 0.032
C4 163.52 0.220 1.000 0.357 0.199 0.078
Anti-dsDNA 162.67 0.125 0.357 1.000 0.370 0.132
Anti-nucleosome antibodies 161.87 0.076 0.199 0.370 1.000 0.227
Tenascin 160.40 0.032 0.078 0.132 0.227 1.000
Categorical Low C3 Low C4 Anti-dsDNA+ Anti-nucleosome+ Tenascin+
AIC 165.45 164.44 163.21 160.25 160.06
Low C3 165.45 1.000 0.314 0.134 0.023 0.020
Low C4 164.44 0.314 1.000 0.268 0.041 0.036
Anti-dsDNA antibodies+ 163.21 0.134 0.268 1.000 0.085 0.076
Anti-nucleosome antibodies+ 160.25 0.023 0.041 0.085 1.000 0.667
Tenascin+ 160.06 0.020 0.036 0.076 0.667 1.000
anti-dsDNA anti–double-stranded DNA
This table compares univariate Cox regression models to predict the escalation of therapy by glucocorticoids based on the Akaike information criterion (AIC). The
lower the value of the AIC, the better the fit of the model. Predictors are treated in the upper part of the table as continuous variables and in the lower part of
the table as categorical variables. Paired comparisons of the quality of each model are illustrated by their respective p values. The thresholds for conventional
biomarkers were reference values, and a cutoff value of 654 ng/ml for tenascin-C was generated using receiver operating characteristic curve analysis to find the
optimal discriminatory threshold to identify patients who would require escalation of glucocorticoids. Boldface type indicates statistically significant values
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cutoffs may have suboptimal sensitivity to capture SLE ex-
acerbations [34, 35], while BILAG-2004 flare definitions
may (as in our study) perform somewhat better [36]. Im-
portantly, we observed flares defined by changes in im-
munosuppressive therapy rather early after the inception
visit (i.e., close to the instant of blood sampling for TNC
measurement), while relapses defined by SLEDAI-2 K or
BILAG-2004 could occur no earlier than at the time of the
next per-protocol visit. Hence, our finding of a possible pre-
dictive value of TNC may in fact relate mainly to very early
flares and/or reflect worsening of baseline activity.
There is a paucity of validated SLE biomarkers that sim-
ultaneously reflect disease activity and, more important,
forecast impending flares. Currently, anti-dsDNA anti-
bodies and complement levels are the only serological pa-
rameters that are routinely used as activity-specific
biomarkers in SLE patient care. However, these traditional
biomarkers are not always appropriate for clinical moni-
toring, because high levels of anti-dsDNA or low levels of
C3/C4 are persistent in some patients with lupus. Re-
cently, anti-nucleosome antibodies were also suggested as
a useful biomarker that may have additional value when
evaluated with traditional biomarkers [37].
We compared the value of univariate models based on
either conventional biomarkers (i.e., anti-dsDNA or anti-
nucleosome antibodies and C3 or C4) or TNC to predict
disease flare (i). In our cohort, serum TNC levels outper-
formed traditional biomarkers when treated as both a
continuous and a categorical variable. It is fair to men-
tion that we used reference threshold values of the con-
ventional biomarkers, while the threshold value for TNC
was generated by a ROC curve analysis for this very pur-
pose using our SLE cohort. However, in daily clinical
practice, conventional biomarkers are always interpreted
in the context of their reference values; hence, such a
comparison with a new investigational biomarker is
sensible. We did not compare the role of conventional
biomarkers with TNC to discriminate between active
versus inactive disease, because anti-dsDNA and com-
plement contribute to the SLEDAI-2 K-2 K score on
which our definition of active disease was based.
Some questions remain. TNC was shown to correlate
with the degree of activity in some diseases and clinical
scenarios [13–15], while in others it appeared to reflect
subsequent tissue remodelling or irreversible damage
[18, 24, 26]. TNC is probably neither disease-specific
nor pathology-specific, but rather a more universal and
ubiquitous marker of ongoing tissue injury, although its
potential for monitoring lupus nephritis may deserve
closer evaluation. Further study in patients with SLE is
required to elucidate whether fluctuations in TNC levels
may be used to herald early and reversible changes (i.e.,
activity) or to signal ongoing fibrosis and progressive
and/or irreversible tissue damage. Interestingly, some
data indicate that GC may suppress TNC expression
[38]. We did not find any correlation with the current
dose of GC (data not shown), and we were unable to
measure the therapeutic response to GC in our cohort
owing to the limited follow-up duration. A much larger
study would be required to evaluate the predictive role
of TNC for long-term organ damage accrual in SLE.
Our study has several strengths. To the best of our
knowledge, this study is the largest to investigate the
role of TNC in SLE to date. Our results seem to be con-
sistent both cross-sectionally (TNC levels discriminated
active from inactive disease and were correlated with the
positivity of traditional biomarkers) and longitudinally
(TNC levels were predictive of future escalations of im-
munosuppressive therapy).
The study has several limitations. It was performed
cross-sectionally in a single SLE cohort with a limited
number of patients. We did not have sufficient follow-
up data to assess the informational value of dynamic
changes in TNC levels and their consistency in serial
samples. We also used an open rather than predefined
time window for a flare to occur during follow-up after
TNC sampling because we were not aware of the “right”
model to choose based on the (unknown) TNC patho-
physiology in SLE.
Conclusions
We found that circulating levels of TNC aided in the
discrimination of patients with SLE with active disease
from HC or patients with no or low disease activity.
Moreover, high levels of TNC were associated with an
increased risk of the need to start or escalate the dose of
GC. Further studies with a larger cohort of patients are
required to validate the role of TNC as a useful serum
biomarker for monitoring disease activity and predicting
flares in patients with SLE.
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